BRPI0620985B8 - composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina - Google Patents

composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina

Info

Publication number
BRPI0620985B8
BRPI0620985B8 BRPI0620985A BRPI0620985A BRPI0620985B8 BR PI0620985 B8 BRPI0620985 B8 BR PI0620985B8 BR PI0620985 A BRPI0620985 A BR PI0620985A BR PI0620985 A BRPI0620985 A BR PI0620985A BR PI0620985 B8 BRPI0620985 B8 BR PI0620985B8
Authority
BR
Brazil
Prior art keywords
triazine derivatives
pharmaceutical composition
insulin sensitizers
sensitizers
insulin
Prior art date
Application number
BRPI0620985A
Other languages
English (en)
Inventor
Cravo Daniel
Mesangeau Didier
Moinet Gérard
Original Assignee
Merck Patent Ges Mit Beschraenkter Haftung
Poxel S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschraenkter Haftung, Poxel S A S filed Critical Merck Patent Ges Mit Beschraenkter Haftung
Publication of BRPI0620985A2 publication Critical patent/BRPI0620985A2/pt
Publication of BRPI0620985B1 publication Critical patent/BRPI0620985B1/pt
Publication of BRPI0620985B8 publication Critical patent/BRPI0620985B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição farmacêutica contendo derivados de triazina e sensibilizadores de insulina, uso de ditos compostos e kit. a presente invenção refere-se a combinações de derivados de triazina e de sensibilizadores de insulina.
BRPI0620985A 2006-01-13 2006-12-18 composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina BRPI0620985B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0600344 2006-01-13
FR0600344A FR2896159B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
PCT/EP2006/012185 WO2007079917A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers

Publications (3)

Publication Number Publication Date
BRPI0620985A2 BRPI0620985A2 (pt) 2011-11-29
BRPI0620985B1 BRPI0620985B1 (pt) 2020-04-28
BRPI0620985B8 true BRPI0620985B8 (pt) 2021-05-25

Family

ID=36654309

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620985A BRPI0620985B8 (pt) 2006-01-13 2006-12-18 composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina

Country Status (22)

Country Link
US (2) US8791115B2 (pt)
EP (1) EP1971330B1 (pt)
JP (1) JP5249782B2 (pt)
KR (2) KR101482685B1 (pt)
CN (1) CN101355933A (pt)
AR (1) AR059032A1 (pt)
AT (1) ATE476179T1 (pt)
AU (1) AU2006334734B2 (pt)
BR (1) BRPI0620985B8 (pt)
CA (1) CA2640897C (pt)
CY (1) CY1110789T1 (pt)
DE (1) DE602006016014D1 (pt)
DK (1) DK1971330T3 (pt)
EA (1) EA015576B1 (pt)
ES (1) ES2347177T3 (pt)
FR (1) FR2896159B1 (pt)
IL (1) IL192558A (pt)
PL (1) PL1971330T3 (pt)
PT (1) PT1971330E (pt)
SI (1) SI1971330T1 (pt)
WO (1) WO2007079917A2 (pt)
ZA (1) ZA200806947B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
SI2355829T1 (sl) * 2008-12-12 2015-03-31 Poxel S.A.S. Kombinacija inzulina z derivati triazina in njegova uporaba za zdravljenje diabetesa
BRPI0922650A2 (pt) * 2008-12-12 2017-07-11 Poxel Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
KR20120011667A (ko) 2010-07-29 2012-02-08 광주과학기술원 당뇨병 치료제의 스크리닝 방법
KR101271218B1 (ko) * 2012-12-07 2013-06-07 광주과학기술원 당뇨병 치료제의 스크리닝 방법
MX2020003243A (es) 2017-10-02 2020-09-18 Poxel Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
WO2019236844A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CN112218623A (zh) 2018-06-14 2021-01-12 博希尔公司 用于治疗糖尿病的包含三嗪衍生物的薄膜包衣片剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5885980A (en) * 1996-06-25 1999-03-23 Enrique G. Gutierrez Composition and method for treating diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
EP1278513B1 (en) * 2000-05-01 2007-07-18 Aeropharm Technology, LLC A core formulation
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
CA2549025A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
FR2863484B1 (fr) * 2003-12-11 2007-04-13 Oreal Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Also Published As

Publication number Publication date
AU2006334734B2 (en) 2012-07-19
DE602006016014D1 (de) 2010-09-16
CN101355933A (zh) 2009-01-28
EP1971330B1 (en) 2010-08-04
ATE476179T1 (de) 2010-08-15
BRPI0620985A2 (pt) 2011-11-29
KR20140033498A (ko) 2014-03-18
SI1971330T1 (sl) 2010-11-30
EP1971330A2 (en) 2008-09-24
WO2007079917A2 (en) 2007-07-19
ES2347177T3 (es) 2010-10-26
IL192558A (en) 2013-04-30
CA2640897A1 (en) 2007-07-19
PL1971330T3 (pl) 2011-01-31
JP2009523142A (ja) 2009-06-18
FR2896159A1 (fr) 2007-07-20
ZA200806947B (en) 2009-11-25
AR059032A1 (es) 2008-03-12
US20100285117A1 (en) 2010-11-11
US8791115B2 (en) 2014-07-29
JP5249782B2 (ja) 2013-07-31
CY1110789T1 (el) 2015-06-10
PT1971330E (pt) 2010-09-09
FR2896159B1 (fr) 2008-09-12
AU2006334734A1 (en) 2007-07-19
BRPI0620985B1 (pt) 2020-04-28
KR101482685B1 (ko) 2015-01-14
CA2640897C (en) 2015-10-20
US20140050786A1 (en) 2014-02-20
WO2007079917A3 (en) 2007-08-30
EA015576B1 (ru) 2011-10-31
DK1971330T3 (da) 2010-10-25
KR20080088630A (ko) 2008-10-02
EA200801676A1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
BRPI0620985B8 (pt) composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina
BRPI0915084B8 (pt) composto, e, composição farmacêutica
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
ECSP10010722A (es) Compuestos orgánicos
BRPI0809977A2 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0922364A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0818804A2 (pt) Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
BRPI0908208A2 (pt) Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
UY30610A1 (es) Moduladores de mglur5
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
BRPI0614730A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0916571A2 (pt) composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: POXEL S.A.S (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.